Andrew Shiflett
Medical · Henrico, VANPI 1689127540
Payments from drug & device makers
Across 258 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$810
- Novo Nordisk$345
- Lilly USA, LLC$283
- Pfizer$247
- Takeda Pharmaceuticals U.S.A., Inc.$243
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$221
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,098100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 52 | $810 |
| Novo Nordisk | 28 | $345 |
| Lilly USA, LLC | 22 | $283 |
| Pfizer | 14 | $247 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $243 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $221 |
| Amgen | 15 | $215 |
| Amarin Pharma, Inc. | 13 | $204 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $179 |
| Upsher-smith Laboratories LLC | 9 | $178 |
| AstraZeneca | 3 | $146 |
| Eisai Inc. | 1 | $122 |
| Biohaven Pharmaceuticals, Inc. | 7 | $119 |
| Merck | 5 | $90 |
| Boehringer Ingelheim | 6 | $90 |
| Currax Pharmaceuticals LLC | 6 | $82 |
| Exact Sciences | 3 | $65 |
| Esperion Therapeutics, Inc. | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| GSK | 3 | $46 |
| Novartis | 2 | $40 |
| Bayer | 2 | $37 |
| Dexcom, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Abbott | 2 | $27 |
| Corium, LLC | 1 | $24 |
| Genentech USA, Inc. | 2 | $22 |
| Mylan Specialty L.p. | 1 | $22 |
| Boston Scientific | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,098 in reported general payments places this provider in the 85th percentile of 632 medical providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $60,791 |
| OzempicSemaglutide | 36 | $37,965 |
| JardianceEmpagliflozin | 48 | $33,883 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $31,870 |
| TrulicityDulaglutide | 31 | $28,850 |
| EntrestoSacubitril/Valsartan | 17 | $15,126 |
| MounjaroTirzepatide | 13 | $14,508 |
| FarxigaDapagliflozin Propanediol | 19 | $11,693 |
| XareltoRivaroxaban | 21 | $11,657 |
| TrintellixVortioxetine Hydrobromide | 13 | $5,770 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 19 | $4,975 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,467 |
| Solifenacin Succinate | 20 | $3,531 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $2,755 |
| Midodrine Hcl | 73 | $2,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $247 | $65,766124 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $283 | $43,35844 claims |
| Novo NordiskOzempic | $345 | $37,96536 claims |
| Boehringer IngelheimJardiance | $90 | $33,88348 claims |
| GSKTrelegy Ellipta | $46 | $31,87048 claims |
| AstraZenecaFarxiga, Symbicort | $146 | $16,16038 claims |
| NovartisEntresto | $40 | $15,12617 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $243 | $5,77013 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $1,725264 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 632 medical providers in Virginia.
Other medical in Henrico
- Bryan UrquhartFredericksburg$264K
- Sara VillalonaRichmond$240K
- Sarah SafaLansdowne$171K
- Waseem GarbiaFairfax$114K
- Rana HassanAshburn$54K
- Brian LamFalls Church$51K
- Christine KesslerKing George$20K
- Janlyn AnthonyRichmond$18K
- Cara DepanfilisNorfolk$17K
- Nicholas DeptulaRichmond$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.